BioPharmSignal logoBioPharmSignal

Biotech News

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

Denali Therapeutics (DNLI)Denali TherapeuticsEarnings

Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026.

Related news

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

TMCITreace Medical Concepts2026-10-23 11:05 EST

Treace to Report Third Quarter 2026 Financial Results on November 6, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OMOutset Medical2026-10-21 20:05 EST

Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

RXSTRxSight2026-10-20 20:05 EST

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

HRMYHarmony Biosciences2026-10-20 12:05 EST

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

IRTCiRhythm2026-10-15 20:05 EST

iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026

ADPTAdaptive Biotechnologies2026-10-14 20:05 EST

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

PRCTPROCEPT BioRobotics2026-10-12 20:05 EST

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

View all latest news

Denali Therapeutics

Blood-Brain-Barrier Delivery Denali Therapeutics develops medicines for neurodegenerative and lysosomal-storage diseases. Its TransportVehicle platform uses transferrin-receptor binding to carry enzymes, proteins and oligonucleotides across the blood-brain barrier. AVLAYAH AVLAYAH, or tividenofusp alfa, is an enzyme TransportVehicle...

Recent company news

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

DNLIDenali Therapeutics2026-07-09 20:01 EST

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

DNLIDenali Therapeutics2026-06-18 12:00 EST

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Stock data

Close
18.66 USD
Market cap
3.07B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States